Lenalidomide Zentiva

Lenalidomide, the active ingredient in Lenalidomide Zentiva, is an immunomodulatory drug (IMiD) presented as an oral tablet for oral use. It is employed in the treatment of multiple myeloma and selected myelodysplastic syndromes in adult patients, where it helps control disease progression and improve blood cell production.

GNH USA supplies Lenalidomide Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies and related bone‑marrow disorders. - Multiple Myeloma: improves progression‑free survival and overall response rates in eligible adult patients. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and enhances hematologic parameters. - Multiple Myeloma (maintenance therapy): prolongs remission duration after initial induction treatment.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Fatigue - Nausea - Low blood cell counts (neutropenia, anemia, thrombocytopenia) Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism - Severe skin reactions such as Stevens‑Johnson syndrome - Hepatotoxicity

When prescribing Lenalidomide, several safety considerations should be observed. - Pregnancy: contraindicated; classified Category X due to teratogenic risk. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Renal impairment: adjust dosing and monitor renal function closely. - Hepatic impairment: use with caution and monitor liver enzymes. - Infection monitoring: watch for signs of serious infections and manage promptly. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, affecting efficacy or safety. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce plasma concentrations. - Anticoagulants (warfarin, direct oral anticoagulants): increased risk of bleeding. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase exposure. - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity. - Vaccines (live attenuated): reduced vaccine efficacy; avoid during therapy.